Allogene Therapeutics

Allogene Therapeutics is set to begin trading on the Nasdaq Stock Exchange under the ticker symbol “ALLO.” The stock is expected to debut Thursday, Oct. 11, although an official IPO date has not yet been released. The Details San Francisco-based Allogene intends to raise $288 million...

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. Allogene Therapeutics, Inc. (ALLO) will issue 16 million shares between $16 and $18 Thursday on the Nasdaq. With a portfolio acquired from Pfizer Inc. (NYSE: PFE), the biotech firm develops allogeneic CAR-T therapies...